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1. Introduction 
Vitamin D is a steroid hormone with such pleiotropic effects as bone and calcium 
homeostasis, as well as immunomodulation, and it exerts its effects via the vitamin D 
receptor (VDR). Vitamin D can be obtained from food as vitamin D3 (cholecalciferol), but is 
also synthesized in the keratinocytes in the epidermis from the precursor molecule 7-
dehydrocholesterol (provitamin D3) by ultraviolet B (UVB) radiation in sunlight to pre-
vitamin D3. Pre-vitamin D3 then undergoes a spontaneous, temperature-dependent 
isomerization to vitamin D3 (cholecalciferol), which enters the dermal capillaries. At this 
point, endogenous vitamin D3 and exogenous dietary D2 (ergocalciferol) undergo 
hydroxylation in the liver to 25-hydroxy Vitamin D (calcitriol). This molecule travels to the 
kidney where it is again hydroxylated to make mature vitamin D (1,25-dihydroxy Vitamin 
D, or 1,25(OH)2D3, which is also known as calcitriol) and 24,25-dihydroxyvitamin D. 
1,25(OH)2D3 is the biologically active form of vitamin D, which regulates serum calcium and 
phosphate homeostasis.(Klaus Wolff 2008) Circulating 1,25(OH)2D3 has a very short half-life 
and is tightly regulated by parathyroid hormone. Fibroblast growth factor 23 (FGF23), 
which is produced in osteoblasts, is also important in regulating 1,25(OH)2D3 production in 
the kidney.(Jurutka, Bartik et al. 2007) 
2. Vitamin D and autoimmune diseases 
There is increasing evidence that vitamin D may have an immunoregulatory role in various 
autoimmune diseases. The mechanism by which vitamin D affects autoimmunity is 
unknown, but there is clear evidence of regulation of immune cells by vitamin D in 
vitro.(Adorini and Penna 2008; Cantorna, Yu et al. 2008) Vitamin D has multiple effects on 
innate and adaptive immune responses through its effects on T and B lymphocytes, 
macrophages, and dendritic cells (DC), all of which express the VDR.(Adorini and Penna 
2008) High levels of 1,25(OH)2D3 inhibit dendritic cell maturation with lower expression of 
major histocompatibility complex (MHC) class II molecules, downregulation of 
costimulatory molecules that are required for antigen presentation, and lower production of 
proinflammatory cytokines such as interleukin (IL)-12.(van Etten and Mathieu 2005; Baeke, 
van Etten et al. 2008) In mouse models, 1,25(OH)2D3 drives the adaptive immune system 
from a T helper Th1/Th17 response toward a Th2 and regulatory T-cell response, suggesting 
the potential beneficial effects of vitamin D on the inhibition of Th1-mediated autoimmune 
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diseases in humans.(Daniel, Sartory et al. 2008) The immune system of VDR-deficient mice 
is grossly normal but shows increased susceptibility to autoimmune diseases such as 
inflammatory bowel disease and type 1 diabetes mellitus.(Bouillon, Carmeliet et al. 2008) In 
addition, 1,25(OH)2D3 may suppress autoimmune diseases by enhancing the production and 
function of regulatory T cells (Tregs), which are vital for preserving peripheral self-
tolerance. 1,25(OH)2D3 plays a role in the activation of Tregs by DCs, by increasing the 
number of Tregs, and enhancing their secretion of IL-10, which inhibits the activation of T 
lymphocytes.(Loser, Mehling et al. 2006; Spach, Nashold et al. 2006) There is some evidence 
that vitamin D may play a regulatory role in autoantibody production by B cells, inhibiting 
the ongoing proliferation of activated B cells and inducing their apoptosis.(Chen, Sims et al. 
2007) Several mechanisms have been proposed to explain the role for vitamin D 
insufficiency in the pathogenesis of autoimmune disorders. 
There are also various reports of vitamin D deficiency associated with several autoimmune 
disorders, including inflammatory bowel disease, multiple sclerosis (MS), systemic lupus 
erythematosus (SLE), type 1 diabetes mellitus, and rheumatoid arthritis (RA).(Cantorna, Yu 
et al. 2008) Furthermore, vitamin D polymorphisms have also been associated with 
increased risk of multiple autoimmune diseases, including Hashimoto’s thyroiditis, 
inflammatory bowel disease, Graves’ disease, rheumatoid arthritis, SLE, primary biliary 
cirrhosis (PBC), autoimmune hepatitis, Addison’s disease, vitiligo, celiac disease, type I 
diabetes mellitus and multiple sclerosis (MS).(Kriegel, Manson et al. 2011) Therefore, 
supplementation of vitamin D can possibly be used as a treatment in autoimmune disease. 
Vitamin D supplementation has been shown to be therapeutically effective in different 
experimental animal models, such as allergic encephalomyelitis, collagen-induced arthritis, 
type 1 diabetes mellitus, inflammatory bowel disease, autoimmune thyroiditis, and systemic 
lupus erythematosus.(Lemire and Archer 1991; Mathieu, Waer et al. 1994; Cantorna, Hayes 
et al. 1998; Cantorna, Munsick et al. 2000; Van Etten, Branisteanu et al. 2003) However, 
despite the in vitro and animal evidence for the promising effects of vitamin D to decrease 
systemic inflammation and prevent autoimmune disease in humans, these findings have 
been somewhat conflicting in humans.  
3. Association between vitamin D and vitiligo 
Vitiligo, an autoimmune pigmentary disorder, is characterized by the aberrant loss of 
functional melanocytes from involved epidermis. The association of vitiligo with 
autoimmune conditions is well-established. Vitiligo is commonly associated with thyroid 
disorders and abnormalities, particularly Hashimoto’s thyroiditis and Grave’s disease, type 
I diabetes mellitus, and Sjögren’s syndrome.(Sehgal, Rege et al. 1976; Niepomniszcze and 
Amad 2001; Montes, Pfister et al. 2003; Adorini and Penna 2008) Low levels of vitamin D 
have also been associated with autoimmune diseases, including rheumatoid arthritis, type I 
diabetes mellitus, and multiple sclerosis.(Adorini and Penna 2008) However, little is known 
about the association of vitiligo and reduced vitamin D levels. 
Silverberg et al. reported that patients with vitiligo who have low levels of vitamin D were at 
higher risk for secondary forms of autoimmunity and that insufficient vitamin D levels were 
associated with increasing Fitzpatrick phototype.(Silverberg, Silverberg et al. 2010) They 
suggested that monitoring vitamin D levels in patients with vitiligo may identify 
individuals at greater risk for secondary autoimmune diatheses. However, there is no 
reliable evidence that vitamin D supplementation can treat or prevent vitiligo.  
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4. Effect of topical vitamin D on vitiligo 
In recent years, topical vitamin D analogues, particularly calcipotriol and tacalcitol, have 
been used as monotherapy or in combination with phototherapy for the treatment of 
vitiligo. Even if their exact mechanism of actions were unclear, vitamin D analogues have 
two different effects on vitiligo in terms of immune function and melanocytes. Vitamin D 
ligands are designed to target the local immune response in vitiligo, acting specifically on T 
cell activation, mainly by inhibiting the transition of T cells from the early-to-late G1 period 
in interphase and by inhibiting the expression of several pro-inflammatory cytokines genes, 
such as those encoding tumor necrosis factor-alpha (TNF-α) and interferon gamma (IFN-γ). 
Vitamin D3 compounds are known to influence melanocyte maturation and differentiation 
and also to up-regulate melanogenesis through pathways activated by specific ligand 
receptors, such as the endothelin receptor and the proto-oncogene c-kit (mast/stem cell 
growth factor receptor [SCFR]).(Birlea, Costin et al. 2008) 
At the molecular level, the addition of vitamin D compounds to a vitiligo treatment regimen 
along with different forms of UV and glucocorticoids can halt disease progression in vitiligo 
by immunosuppression and possibly induce repigmentation by activating melanocyte 
precursors and the promotion of melanogenic pathways.(Birlea, Costin et al. 2009) 
However, the true effects of vitamin D analogues on vitiligo remain controversial (Table 1). 
Some studies have reported a good response or even an augmented response to them over 
conventional vitiligo therapies, whereas other studies have reported no response to or only 
limited effects of vitamin D analogues.(Leone, Pacifico et al. 2006; Lu-yan, Wen-wen et al. 
2006; Goldinger, Dummer et al. 2007; Rodriguez-Martin, Garcia Bustinduy et al. 2009) One 
of the authors (SHO) published a prospective study which showed that the use of high 
concentration tacalcitol had a limited effect as either monotherapy or as part of combination 
therapy with excimer laser in the treatment of vitiligo.(Oh, Kim et al. 2011) 
 
Treatment 
Type of 
Vitamin D 
Study 
design 
Results Effect References 
Tacalcitol 
ointment 
(4μg/g)+ 30min 
sunlight daily 
vs placebo + 
sunlight 
Tacalcitol 
Randomized, 
double-
blinded, 
placebo-
controlled 
Placebo+heliotherapy: 
1/31 
Tacalcitol+heliothera
py: 0/32 >75% 
repigmentaton after 4 
months 
No 
(Rodriguez
-Martin, 
Garcia 
Bustinduy  
et al. 2009) 
NB-UVB vs NB-
UVB+ tacalcitol 
(4μg/g) 
Tacalcitol 
Randomized, 
investigator 
blinded, 
controlled, 
left-right 
trial 
NB-UVB: 0/32 
NB-UVB+tacalcitol: 
16/32 (50%) >80% 
repigmentation after 
6 months 
Yes 
(Leone, 
Pacifico  
et al. 2006) 
Excimer light 
once weekly+ 
placebo vs 
excimer 
light+tacalcitol 
(2μg/g) 
Tacalcitol 
Randomized, 
double-
blinded, 
placebo-
controlled, 
left-right 
trial 
MEL+placebo: 2/35 
(5.7%) 
MEL+tacalcitol: 9/32 
(25.7%) >75% 
repigmentation after 
12 treatments (3 
months) 
Yes 
(Lu-yan, 
Wen-wen  
et al. 2006) 
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Treatment 
Type of 
Vitamin D 
Study 
design 
Results Effect References 
Untreated vs 
calcipotriol 
Calcipotriol 
Prospective, 
left/right 
comparative, 
open study 
3/24: partial response 
Of 3 patients showing 
response  
1: 5% repigmentation 
(only treated area)  
2: 20% 
repigmentation (both 
treated and untreated 
areas)  
3: 30% 
repigmentation 
(treated), 10% 
repigmentation 
(untreated) 
No 
(Chiaverini, 
Passeron  
et al. 2002) 
Betamethasone 
vs 0.005% 
calcipotriol vs 
betamethasone/ 
calcipotriol 
Calcipotriol 
Randomized, 
non-placebo 
controlled 
study 
All groups: no 
patients >75% 
repigmentation 
Betamethasone: 2/15, 
Calcipotriol: 1/15, 
Betamethasone/ 
calcipotriol: 4/15 50-
75% repigmentation 
Time to 
repigmentation was 
faster in combination 
treatment 
No 
(alone) 
Yes 
(combi-
nation) 
(Kumaran, 
Kaur et al. 
2006) 
NB-UVB thrice 
weekly vs NB-
UVB+ 
calcipotriol 
(0.05%) 
Calcipotriol 
Randomized, 
non-placebo 
controlled 
study 
NB-UVB: 10/24 
(41.67%) 
NB-UVB + 
calcipotriol: 6/13 
(46.2%) 50-100% 
repigmentation after 
30 treatments 
(10weeks) 
No 
(Arca, 
Tastan  
et al. 2006) 
PUVA+placebo 
vs PUVA+ 
calcipotriol 
(0.05mg/g-
0.005%) 
Calcipotriol 
Randomized, 
double-
blinded, 
placebo-
controlled, 
left-right 
trial 
PUVA+placebo: 
30.07±1.34 treatments  
PUVA+calcipotriol: 
27.4±1.47 treatments 
(time to complete 
repigmentation) 
Yes 
(Ermis, 
Alpsoy  
et al. 2001) 
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Treatment 
Type of 
Vitamin D 
Study 
design 
Results Effect References 
PUVAsol+ 
placebo vs 
PUVAsol+calci
potriol  
(50μg/g-0.005%) 
Calcipotriol 
Randomized, 
double-
blinded, 
placebo-
controlled, 
left-right 
trial 
PUVAsol+placebo: 
9/17 (52.9%)  
PUVAsol+calcipotriol: 
13/17 (76.5%) >75% 
repigmentation after 
18 months 
Yes 
(Parsad, 
Saini et al. 
1998) 
Excimer laser 
thrice week vs 
excimer laser 
+calcipotriol 
(0.005%) 
Calcipotriol 
Randomized, 
single-
blinded, left-
right trial 
Excimer: 22% 
Excimer +calcipotriol: 
23% mean 
repigmentation after 
8 weeks 
No 
(Goldinger, 
Dummer  
et al. 2007) 
Excimer laser 
twice a week vs 
excimer laser 
+high 
concentration of 
tacalcitol 
High 
concentration 
of tacalcitol 
Randomized, 
single-
blinded, left-
right trial 
Excimer vs Excimer + 
tacalcitol: no 
significant difference 
No 
(Oh, Kim  
et al. 2011) 
μg/g: microgram/gram, vs: versus, NB-UVB: narrowband ultraviolet B, MEL: monochromatic excimer 
light, PUVA: psoralen and ultraviolet A, mg/g: milligram/ gram, PUVAsol: psoralen and sun exposure 
Table 1. Randomized, controlled studies regarding the effect of vitamin D on the treatment 
of vitiligo 
Vitamin D analogues as monotherapy are less effective than topical corticosteroids in 
vitiligo, although there is some evidence of an additive effect with combining the two. 
(Hossani-Madani and Halder 2011) There is no convincing evidence to suggest that topical 
vitamin D analogues in combination with phototherapy, i.e., narrowband UVB (NB-UVB), 
psoralen and ultraviolet A (PUVA), or 308 nanometer (nm) excimer laser, are superior to 
phototherapy alone. Gawkrodger et al. recommended that topical vitamin D analogues in 
combination with NB-UVB or PUVA therapy should not be used in the treatment of 
vitiligo.(Gawkrodger, Ormerod et al. 2008)  
5. Conclusion 
Vitiligo is generally considered to be an autoimmune disorder. There is preliminary 
evidence that vitamin D deficiency could be causally related to a variety of autoimmune 
diseases. There have been some reports showing good responses to topical vitamin D 
analogues alone or as part of combination treatment with phototherapy. However, future 
studies are required to evaluate the relationship of serum vitamin D levels and vitiligo, as 
well as to elucidate the effects of vitamin D in vitiligo. The utility of topical vitamin D agents 
in the treatment of vitiligo also needs to be substantiated. 
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